Summary Thymidylate synthase (TS) expression has been characterized for a panel of eight human colorectal carcinoma and five human leukaemia cell lines, to relate differences in intrinsic TS activity, protein and mRNA levels to growth inhibition caused by continuous exposure to THYMITAQTM, a specific non-classical antifolate TS inhibitor. Although a 20-fold variation in sensitivity to THYMITAQTM was found within the colorectal cell line panel (IC50 0.12-2.7 gM), sensitivity was not related to TS activity, TS protein or TS mRNA levels. For the leukaemic cell lines, only a twofold range in sensitivity to THYMITAQTM was observed (IC50 0.87-2.3 ,M), and this did not correlate with TS activity, TS protein or TS mRNA levels. Across all of the cell lines, TS activity was linearly related to TS protein levels (r2 = 0.87, P < 0.0001). However, for both the colorectal and leukaemia cell line panels, no relationship was found between TS mRNA/1 8S rRNA ratios and either TS activity or TS protein, consistent with the importance of post-transcriptional mechanisms in regulating TS activity. Two of the colorectal cell lines (BE and HCT116) and one of the human leukaemic cell lines (HL60), were intrinsically resistant to THYMITAQTM (IC50 > 2 giM) in the absence of TS overexpression, suggesting that, subsequent to TS inhibition, events such as DNA repair and tolerance to apoptotic stimuli are also important determinants of sensitivity to THYMITAQTM.
Thymidylate synthase (TS; EC 2.1.1.45) is an important enzyme in pyrimidine biosynthesis catalysing the rate-limiting step of de novo thymidylate synthesis. Thymidylate is used exclusively in DNA replication and TS therefore constitutes an attractive target for antiproliferative chemotherapy. TS catalyses the conversion of deoxyuridine monophosphate (dUMP) to thymidylate (dTMP), using 5,10-methylene tetrahydrofolate (5,10-CH2FH4) as the methyl-donating co-substrate.
TS can be inhibited by pyrimidine (Pinedo and Peters, 1988) or folate substrate antagonists , and antitumour efficacy has been found with both classes of drug (Touroutoglou and Pazdur, 1996) . The activity of TS inhibitors can be influenced by a number of parameters, including cellular uptake, anabolism, catabolism, TS levels and activity, and the response of the cell to thymidylate deprivation. Among these parameters, TS expression has been shown to be an important determinant of acquired resistance to TS inhibitors in vitro (O'Connor et al, 1992; . However, the importance of TS expression has generally been investigated in cell lines that have been made resistant by exposure to increasing concentrations of TS inhibitors, such as 5-fluorouracil (Peters et al, 1986) or folate-based antagonists (O'Connor et al, 1992; . In the clinical setting, TS protein and TS gene transcript levels have also been found to relate to the responsiveness of patients with colorectal and gastric carcinoma to 5-FU-based chemotherapy (Johnston et al, 1995) .
In relating measures of TS expression to cellular sensitivity to fluorinated pyrimidines and classical antifolates, a number of factors need to be considered. For example, as well as causing inhibition of TS, metabolites of 5-fluorouracil (5FU) and fluorodeoxyuridine (FdUrd) are also incorporated into RNA and DNA, which may also produce a cytotoxic effect (Pinedo and Peters, 1988) . Similarly, classicar antifolate TS inhibitors require specialized membrane proteins to mediate uptake (Jansen et al, 1990) and are substrates for intracellular polyglutamation by the enzyme folylpolyglutamyl synthetase (FPGS), which markedly enhances their intracellular retention and potency Touroutoglou and Pazdur, 1996) . Furthermore, antifolate polyglutamates are substrates for hydrolysis and the activity of the hydrolase responsible can also influence sensitivity to antifolates (Rhee et al, 1993) .
The studies reported here were performed to investigate the relationship between TS expression in human leukaemia and colorectal carcinoma cell lines and growth inhibition caused by the novel TS inhibitor THYMITAQTM. THYMITAQTM is a non-classical antifolate TS inhibitor that has been designed to overcome some of the potential mechanisms of resistance to classical antifolates (Webber et al, 1993) . THYMITAQTm acts solely as a TS inhibitor, does not require specialized transport proteins for cellular uptake and is not a substrate for polyglutamation (Webber et al, 1996) . The relationhip between TS expression and the sensitivity of cell lines to THYMITAQTM should, therefore, be more direct than in the case of classical antifolates or fluoropyrimidinebased TS inhibitors. Colorectal and leukaemic cell lines were chosen as being representative of solid and haematological malignancies in which TS inhibitors or antifolates have an established clinical role.
MATERIALS AND METHODS
Several methods for measuring TS expression have been described. TS activity may be measured directly as the rate of release of 3H20 from [3H]dUMP, either using [3H]uridine in a whole-cell in situ assay (e.g. Taylor et al, 1988) or by using a cellfree extract (e.g. Calvert et al, 1980) . TS protein levels can be assessed using immunohistochemistry (Van der Wilt et al, 1993) , Western blot analysis (Freemantle et al, 1995) and by an enzymelinked immunosorbent assay using either polyclonal (Freemantle et al, 1995) or monoclonal antibodies (Johnston et al, 1993) . TS protein content can also be measured using the FdUMP binding assay (Peters et al, 1991) . With regard to TS gene expression, the use of Northern blot hybridization (O'Connor et al, 1992) and reverse transcriptase PCR (Freemantle et al, 1995; Johnston et al, 1995) to measure TS mRNA has been described. In the present study, TS activity was measured in cellfree extracts using a 3H2O release assay, TS protein by quantitative Western blotting and TS mRNA by Northern blot hybridization.
Tissue culture of human leukaemia and human colorectal cell lines
The human leukaemia cell lines Molt4, Jurkat and CCRF-CEM (Tcell), HL60 (promyelocytic) and K562 (erythroleukaemic) were maintained as cell suspensions, and the human colorectal carcinoma cell lines Colo2O5, SW48, SW480, SW620, HT29, HCT1 16, BE and LoVo were grown as adherent monolayers. All cell lines were grown in RPMI-1640 tissue culture medium (Gibco/BRL, Paisley, UK), supplemented with charcoal-dialysed, i.e. thymidine-depleted, 10% (v/v) fetal calf serum (Globepharm, Esher, Surrey, UK), 2 mm L-glutamine (Gibco/BRL) and 7.5% (w/v) sodium bicarbonate solution (Gibco/BRL). The cell lines were routinely subcultured twice weekly to maintain cell counts in the range of 4x105 ml'-to 1 x 106 ml-' and were grown at 37°C in a humidified atmosphere containing 5% carbon dioxide. All cell lines were obtained from the European Collection of Animal Tissue Cultures, with the exception of BE cells, which were kindly provided by Dr J Plumb (Beatson Institute, Glasgow UK) and were regularly tested to exclude mycoplasma infection.
Determination of IC50 values
THYMITAQTM was provided by Agouron Pharmaceuticals (San Diego, CA, USA). THYMITAQTM was dissolved in distilled, deionized water to produce a stock 1 mg ml-' solution. IC50 measurements were performed using exponentially growing cell lines. Cells were exposed to THYMITAQTM continuously for approximately four cell-doubling times (96 h for all cell lines except HL60 for which 120 h was used). Continuous exposure was chosen as a 5-day continuous intravenous infusion schedule, which is the THYMITAQTM protocol most extensively studied in clinical trials. For the human leukaemia cell lines, 0. 1-ml volumes were seeded into each well of a Nunclon round-bottomed 96-well plate at 4 x 105 ml-l (1 x 105 ml-I for HL60 cell line). After 24 h, THYMITAQTm at varying concentrations was added to the six replicate wells. The cells were exposed to the cytotoxic agent for 96 h (120 h for the HL60 cell line). For the colorectal carcinoma cell lines, 2 ml of a freshly prepared cell suspension of 5 x I04 ml-' was seeded into each well of a six-well plate and, after 24 h, triplicate wells were exposed to varying concentrations of THYMITAQTM for a 72-h period.
At (Freemantle et al, 1991) . A 1 in 500 dilution of an '25I-labelled anti-rabbit IgG (donkey, F(ab)2frag-ment; Amersham) was used for secondary detection. The radioactivity present on the membrane was quantified using PhosphorImager analysis (Molecular Dynamics, Sunnyville, CA, USA), and the bands present were referenced to the position on the membrane occupied by the components of the molecular weight markers and the TS standards. For each gel, a linear regression analysis of the signals from the TS standards was performed, and the regression equation was used to quantify the signal obtained for each cell line. Parallel Coomassie blue-stained gels were performed to monitor the quality and relative amounts of total protein per track.
Northern blot hybridization Exponentially growing cell lines were harvested as described for the TS activity assay and were washed in phosphate-buffered saline; total RNA was isolated from cell pellets using RNAzol B (Cinna/Biotex Laboratories International, Frienswood, TX, USA; Chomczynski and Sacchi, 1987) . The RNA was dissolved in 80 jil of RNAase-free water, and the RNA was quantified by measurement of the optical density (OD) at 260 nm. The OD2w/OD280 was used to estimate the purity of the nucleic acids and was always in the range of 1.8-2.0. For each cell line, a volume containing 20 jig of total RNA was denatured by glyoxylation, and the RNA was fractionated by electrophoresis on a 1.2% (w/v) agarose gel. RNA was then transferred to an exact-sized Hybond-N nitrocellulose membrane (Amersham) by overnight blotting. After deglyoxylation in boiling water, the membranes were then hybridized under standard conditions at 65'C to a gel-purified 0.7-kb fragment of mouse cDNA cleaved from the pMTS plasmid (Geyer et al, 1984) with HindIlI and PstI and were labelled with 32p by random primer extension (Feinberg and Vogelstein, 1983) . After overnight hybridization, the membrane was then washed twice with 2 x standard saline citrate (SSC)/0.2% (v/v) SDS to remove any probe that had not specifically bound to TS mRNA, and the TS mRNA signal for each cell line was detected and quantified using the Phosphorlmager system.
The same membranes were re-probed for 18S ribosomal RNA to check the relative loading and transfer efficiency of the RNA samples. The membrane was stripped by boiling in 0.2% SDS/O.lxSSC. The membrane was reprobed as above using a cDNA probe against 18S ribosomal RNA as a surrogate measure of total RNA. The 18S rRNA probe was synthesized from the DNA product generated by polymerase chain reaction (PCR) amplification of a bladder cDNA sample using the 18S specific primers (SN: ATGCTCTTAGCTGAGTGTCC, ASN: AACTAC-GACGGTATCTGATC). The 18S ribosomal RNA signal for each cell line was detected and quantified using the Phosphorlmager system, and the TS mRNA: 18S rRNA ratio was calculated.
Statistics
With the exception of TS mRNA, linear regression analysis was used to investigate the relationship between measures of TS expression and THYMITAQTM IC50. In addition, the Kendall Rank correlation test was used to test for significant rank correlations between TS mRNA and TS protein levels, TS activity levels and THYMITAQTM IC50. The two-sided t-test was used to investigate the difference between TS activity and TS protein levels between the leukaemic and colorectal cell line panels.
RESULTS

Growth-inhibitory activity of THYMITAQTM
The concentrations of THYMITAQTm required to inhibit the growth of exponentially growing human leukaemia and colorectal carcinoma cell lines by 50% of control (IC50) are given in Table 1. A 20-fold range in sensitivity to THYMITAQTM was found within the group of colorectal cell lines, whereas only a 2.5-fold variation in THYMITAQTM sensitivity was seen between the leukaemic cell lines. In general, the colorectal cell lines were 2-3 times more sensitive to THYMITAQTM than the leukaemia cell lines, although the BE and HCT1 16 cell lines had IC50 values that were equivalent to the HL60 cell line, which was the least sensitive leukaemic cell line.
TS activity
A three-fold variation in TS activity was seen within the leukaemic cell line group, with the K562 cell line having the highest TS activity ( Table 1) found between the SW48 and the HCTl 16 cell lines. Overall, significantly higher TS activity was observed with the leukaemic cell lines than with the colorectal cell lines (P = 0.0002, twosided t-test), with mean (± standard deviation) TS activities of 2.5 ± 1.08 nmol dUMP 10-cells h-1 vs 0.21 ± 0.22 nmol dUMP/ 10--cells h-I respectively. TS activity could not be accurately measured in the LoVo cell line because of very high intrinsic phosphatase activity.
TS protein
Representative Western blots for the colorectal cell line panel are shown in Figure IA and B, and the levels of TS protein measured are presented in Table 1 . A threefold variation in TS protein content was found within the colorectal panel, with the HCT116, BE and LoVo cell lines having the highest levels. A representative Western blot for the leukaemic cell line panel is shown in Figure IC . Less variation in TS protein content was observed within the leukaemic panel, i.e. less than a 1.5-fold difference in TS protein level was seen between the cell lines. Overall, significantly higher TS protein levels were found for the leukaemic panel than for the colorectal cell lines (P < 0.0001; two-sided t-test), with approximately fivefold higher TS protein contents of 170 ± 40 pg gg-' total protein vs 35 ± 10 pg ,ug-' total protein respectively (mean ± standard deviation). TS protein could not be detected in the HL60 cell line, possibly as a result of excessive protein degradation (as indicated by the lack of protein bands on Coomassie blue-stained gels; data not shown).
Linear regression analysis of the rhTS standard curve on each gel always gave a highly significant positive correlation, with r2 values above 0.94 in each of the nine gels analysed (mean ± standard deviation of 0.97 ± 0.02). To determine the inter-assay variation of this method, TS protein was measured for a single-cell sonicate from each of the human leukaemia cell lines on three separate occasions.
The following results were obtained (pg jg-' total protein): K562 = 180 ± 40; Molt4 = 130 ± 60; Jurkat = 160 + 60; CCRF-CEM = 130 20 (expressed as mean ± standard deviation).
TS mRNA
A threefold variation in the TS mRNA/18S rRNA ratio was found between the human leukaemia cell lines (Figure 2A ). The highest expression of TS mRNA relative to 1 8s rRNA was found in the CCRF-CEM cell line, and the lowest in the HL-60 cell line. However, RNA extracted from the HL-60 cell line was consistently found to be degraded (Figure 2A) . Similarly, for the colorectal carcinoma cell lines, a twofold variation in TS mRNA/18 s rRNA was found, with the highest TS mRNA levels being found in the SW48, SW480, SW620 and HCT116 cell lines, and the lowest expression found in LoVo and Colo2O5 cells ( Figure 2B ). (1997) 76(12), 1579-1585 There-was no significant linear relationship between TS protein and THYMITAQTM IC50 for either the colorectal cell line panel (r2 = 0.36, P = 0.11) or the leukaemic cell line panel (r2 = 0.38, P = 0.37). Similarly, there was no correlation between TS mRNA expression and THYMITAQTM IC50 (P > 0.5) for either the colorectal or leukaemic cell lines. Investigation of potential relationships using a non-parametric method (Kendall Rank correlation analysis) produced similar conclusions to the statistical analysis using the above parametric tests.
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Relationships between TS activity, protein and mRNA and the growth-inhibitory activity of THYMITAQTM When the measurements for the colorectal and leukaemic cell line panels were combined, a highly significant positive linear correlation (r2 = 0.87, P = 0.00002) was found between TS protein and TS activity (Figure 3) . For the colorectal cell lines alone, a positive linear correlation was also found between TS protein and TS activity (r2 = 0.48, P = 0.08), but this did not reach statistical significance at the 5% level. Neither TS activity or TS protein was found to relate to TS mRNA/18s rRNA ratios as determined using the Kendall Rank correlation test, with either separate or pooled data for the colorectal and human leukaemia cell lines. When analysed separately, there was no significant linear relationship between TS activity and THYMITAQTM IC50 for either colorectal (r2 = 0.4, P = 0.13) or human leukaemia (r2 = 0.29,
DISCUSSION
The aim of this study was to characterize intrinsic TS expression in a panel of human colorectal and leukaemia cell lines to investigate the relationship between TS activity, protein levels and mRNA, and the growth-inhibitory activity of THYMITAQTM, a specific non-classical antifolate TS inhibitor. Previous studies using both colorectal and lymphoblastic cell lines with acquired resistance to TS inhibitors have demonstrated an associated overexpression of TS. Copur et al (1995) described the development of 5-FU resistance within the H630 cell line, in which tenfold resistance to 5-FU was associated with a 23-fold increase in TS activity and TS protein levels, and an 18-fold increase in TS mRNA/3-actin RNA ratio. Similarly, the development of acquired resistance to Tomudex has been characterized in a variety of cell lines, including the lymphoblastic cell line W1-L2 and the human ovarian carcinoma cell line CH1 (Freemantle et . For the W1-L2 cell line, resistance to Tomudex was associated with a 514-fold increase in TS activity, a 180-fold increase in TS protein levels and a 128-fold increase in the TS mRNA/18S rRNA ratio. TS overexpression was less pronounced in the CHI cell line, in which a fourfold increase in TS activity, twofold increase in TS protein and, possibly, a twofold increase in TS mRNA levels was demonstrated. In both cell lines, defects in polyglutamation were also observed, emphasizing the potential importance of the latter as a mechanism of resistance to classical antifolate TS inhibitors.
The finding in the studies reported here, i.e. that, across all of the cell lines studied, there was a highly significant correlation between TS activity and TS protein as measured by quantitative Western blotting, is in keeping with the relationships reported by . Moreover, the finding of higher TS activity and TS protein levels in the leukaemic cell lines is consistent with another report comparing the TS activities of haematological and colorectal cell lines, in which the human lymphoblastoid cell line W1-L2 was found to have a 10-to 20-fold higher TS activity than a panel of human colorectal carcinoma cell lines (Van der Wilt et al, 1993) .
In the studies reported here, sensitivity to THYMITAQTM within the panel of colorectal cell lines did not correlate with cellular TS protein content, for which the 20-fold range in THYMITAQTM IC50 values was related only to a fourfold variation in TS protein levels. This lack of a statistically significant correlation may have resulted both from the relative lack of sensitivity of the methodology used in the present study for determining small differences in TS protein expression, and from the finding of a relatively high TS protein content for the THYMITAQTM-sensitive LoVo cell line. A similar lack of a relationship between TS protein expression and sensitivity to TS inhibition by 5-fluorouracil has also been reported for human colorectal carcinoma cell lines (Berger and Berges, 1988) .
Although in the present study the correlation between TS activity and THYMITAQTM IC50 did not reach statistical significance, this was largely because of the BE cell line. In BE cells, there was only moderate TS activity, which would not have been expected on the basis of the relatively high TS protein levels, and yet lack of sensitivity to THYMITAQTM. Also, in contrast to the results from one clinical study with 5-FU (Johnston et al, 1995) , there was no correlation between sensitivity to THYMITAQTm and TS mRNA expression in the colorectal cell lines. For the human leukaemia cell lines, a smaller range of TS expression was seen, and again no significant correlations were found between TS mRNA levels and sensitivity to THYMITAQTM. In the present study, two of the colorectal adenocarcinoma cell lines (HCTl 16 and BE) and the promyelocytic HL60 cell line were found to display reduced sensitivity to THYMITAQTM, which would not have been predicted solely on the basis of their TS expression. When these cell lines were excluded from the analyses, a significant relationship between both TS activity and TS protein levels and the sensitivity to THYMITAQTM-mediated growth inhibition was found when the results of the colorectal and leukaemic cell line panels were combined. This finding suggests that factors other than TS expression can play an important role in determining the sensitivity of cell lines to THYMITAQTM. As THYMITAQTm does not require active or facilitated transport and is not a substrate for polyglutamation, other factors must underline the differential sensitivity of the cell lines. Specifically, these factors may include cellular biochemical events 'downstream' of TS inhibition. For example, an increased capacity to repair DNA damage (Canman et al, 1992 ) and bcl-2-mediated tolerance to apoptotic stimuli (Fisher et al, 1993) have been reported to cause variations in the sensitivity of colorectal cell lines to both 5-fluorouracil and antifolate TS inhibition. These factors may also have contributed to the lack of a significant correlation between measures of TS expression found in the colorectal cell line panel in the present study and of sensitivity to THYMITAQTM. Resistance to TS inhibition resulting from mutation of the target enzyme has also been reported, finding reduced sensitivity to 5-FU in a HCT1 16 cell line, which resulted from a novel, more basic charge form of TS. Specifically, the mutation was found to result from a tyrosine to histidine replacement at residue 33 of TS (Barbour et al, 1992) . It is not currently known whether or not this or a similar mutation is present in the HCT1 16 cells used in the present study; and, if the mutation is present, the impact of this mutation on THYMITAQTM sensitivity is also not known.
Neither TS protein nor TS activity were found to correlate with the TS mRNA/I8S rRNA ratio in either the colorectal adenocarcinoma or leukaemic cell line panels. The lack of a relationship may possibly be explained by the finding that TS protein can regulate its own transcription (Chu et al, 1991) , with protein levels not being a simple function of transcript concentration. Variation in this feedback mechanism may exist between different cell lines. Therefore, measurement of TSmRNA in a heterogenous population of cell lines may be a poor predictor of sensitivity to TS inhibition.
In summary, neither the colorectal or the leukaemia cell line panels demonstrated a significant correlation between measures of TS expression and sensitivity to THYMITAQTM-mediated growth inhibition. THYMITAQTm resistance, which would not have been predicted solely on the basis of TS expression, was demonstrated in two of the colorectal and one of the leukaemia cell lines, suggesting that events downstream of TS inhibition can be important determinants of the growth-inhibitory activity of THYMITAQTM. There were no correlations between TS activity or TS protein and TS mRNA/18s rRNA ratios in either of the cell line panels, suggesting that TS expression as measured by TS mRNA alone may not be predictive of sensitivity to THYMITAQTM. Future studies will examine the prognostic significance of TS expression for response to THYMITAQTM in adult patients with colorectal carcinoma and in children with acute lymphoblastic leukaemia at both presentation and relapse.
